ComplianceOnline

Extractables and Leachables in Early Phase Development

Instructor: Wayland Rushing
Product ID: 704517
  • 25
  • January 2018
    Thursday
  • 10:00 AM PST | 01:00 PM EST
    Duration: 60 Min

Live Online Training
January 25, Thursday 10:00 AM PST | 01:00 PM EST | Duration: 60 Min

$229.00
One Dial-in One Attendee
$549.00
Group-Max. 10 Attendees/Location
(For Multiple Locations Contact Customer Care)
Super Deal - Get CD/USB Drive Free!

recorded version

$279.00
1x Person - Unlimited viewing for 6 Months
(For multiple locations contact Customer Care)
Recorded Link and Ref. material will be available in My CO Section 48 hrs after completion of Live training

Training CD / USB Drive

$379.00
One CD/USB is for usage in one location only.
(For multiple locations contact Customer Care)
CD/USB and Ref. material will be shipped within 15 business days after completion of Live training

Combo Offers

Live + Recorded Version

$379.00

Live + Training CD/USB

$449.00

Customer Care

Fax: +1-650-565-8542

Email: customercare@complianceonline.com

Read Frequently Asked Questions

This training program will offer insight into where extractables and leachables come from. Attendees will learn the regulatory expectations and trends for extractables and leachables in early phase development and learn which products may require E&L data in early phases. The program will also focus on how to design programs to meet the needs of early phase development – i.e. phase appropriate E&L programs.

Why Should You Attend:

For many years, it has been more or less conventional wisdom that E&L data is a late-stage development concern, but current trends suggest this is changing. In recent months, the FDA has required multiple drug sponsors to provide detailed E&L packages and/or address specific questions in relation to E&L as early as Phase I. Questions have not only involved clinical trial container/closures systems, they also have signaled concern about equipment used in manufacturing of materials and devices used for dosing (i.e. infusion sets).

Unanticipated regulatory scrutiny has caused several programs to be placed on clinical hold pending submission of E&L data, resulting in development delays and unplanned expense. This presentation will review regulatory trends, the nature of questions sponsors have been required to answer, and the types of programs encountering these issues. It will also provide guidance on how to design phase-appropriate E&L programs to address early phase expectations.

Learning Objectives:

  • Understanding where extractables and leachables come from
  • Learning the regulatory expectations and trends for extractables and leachables in early phase development
  • Understanding which products may require E&L data in early phases
  • How to design programs to meet the needs of early phase development – i.e. phase appropriate E&L programs

Areas Covered in the Webinar:

Background and Overview of Extractables and Leachables

  • What are extractables and leachables
  • Where do they come from
  • Why is there concern

Regulatory Requirements of Extractables and Leachables

  • What is required for E&L

Current Regulatory Trends - Early Phase Development

  • What is being requested and why
  • Review of what types of products are getting E&L requests – are there any trends
  • Designing E&L studies to meet the unique needs of early phase development

Who Will Benefit:

  • Drug Development Professionals
  • CMC Analytical Chemists and Leads
  • Manufacturing
  • Quality Assurance
  • Regulatory Affairs
  • Program Management
  • Clinical Leads
Instructor Profile:
Wayland Rushing

Wayland Rushing
Sr Scientific Advisor, ABC Laboratories

Dr. Wayland Rushing is a technical expert in chemistry, manufacturing and controls (CMC) program design, analytical development and regulatory submissions. Over his 15-year career, he has led CMC development programs for a wide array of biopharmaceuticals, including parenterals, inhalation drugs, and other pharmaceuticals with complex delivery systems.

Dr. Rushing is a subject matter expert in HPLC and GC method development and validation, extractables and leachables program design and regulatory submission requirements; has drafted multiple IND and NDA submissions; and assists ABC clients in responding to FDA deficiency letters. He currently serves on Parenteral Drug Association (PDA) advisory committees for Technology Transfer and Elastomeric Closures and Seals Presentation Summary and was co-author of PDA TR 65, Technology Transfer.

Follow us :
Upcoming In-person Seminars by EX-FDA OFFICIALS
PV (Pharmacovigilance) Audit Strategy Planning

Refund Policy

Registrants may cancel up to two working days prior to the course start date and will receive a letter of credit to be used towards a future course up to one year from date of issuance. ComplianceOnline would process/provide refund if the Live Webinar has been cancelled. The attendee could choose between the recorded version of the webinar or refund for any cancelled webinar. Refunds will not be given to participants who do not show up for the webinar. On-Demand Recordings can be requested in exchange.

Webinar may be cancelled due to lack of enrolment or unavoidable factors. Registrants will be notified 24hours in advance if a cancellation occurs. Substitutions can happen any time.

If you have any concern about the content of the webinar and not satisfied please contact us at below email or by call mentioning your feedback for resolution of the matter.

We respect feedback/opinions of our customers which enables us to improve our products and services. To contact us please email customercare@complianceonline.com call +1-888-717-2436 (Toll Free).

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product! Write review

Best Sellers
You Recently Viewed
    Loading